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Controlled ovarian hyperstimulation (COH) which combines GnRH antagonist co-treatment and GnRH-agonist
(GnRHa) trigger has become a common tool aiming to eliminate severe early OHSS and to support the concept of
an OHSS-free clinic. However, due to the reported significantly reduced clinical, efforts have been made to improve
reproductive outcome. One of the suggested optional strategies aiming to improve outcome was the addition of
low-dose (1500 IU) HCG bolus, administered, concomitant, 35 h or 5 days after the triggering bolus of GnRHa. All
these regimens were demonstrated to rescue the luteal phase, resulting in improved reproductive outcome in
patients at risk to develop severe OHSS, compared to GnRHa trigger alone, however, with the questionable ability
to eliminate severe OHSS.
Moreover, following the observations demonstrating comparable or even better oocyte\embryos quality following
GnRHa, compared to hCG trigger, and the different effects of LH and hCG on the downstream signaling of the LH
receptor, GnRHa is now offered concomitant to the standard hCG trigger dose to improve oocyte/embryo yield
and quality. GnRHa and hCG may be offered either concomitantly, 35–37 h prior to oocyte retrieval (dual trigger), or
40 h and 34 h prior to oocyte retrieval, respectively (double trigger).
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Assisted reproduction technology (ART) practitioners
seek a balance between optimum ovarian stimulation
and successful treatment outcome with minimal rate of
severe ovarian hyperstimulation syndrome (OHSS) or
multiple pregnancies.
During IVF treatment, human chorionic gonadotropin
(hCG) is usually used as a surrogate LH surge to induce
luteinization of the granulosa cells, final oocyte matur-
ation and resumption of meiosis. Since OHSS almost al-
ways presents either 3–7 days after hCG administration
in susceptible patients (early onset) or during early
pregnancy, 12–17 days after hCG administration (late
onset), withholding the ovulation-inducing trigger of
hCG with the consequent of cycle cancellation, was used to
eliminate severe early OHSS. However, since cancellation
denotes patient’s frustration and is associated with time andCorrespondence: raoul.orvieto@sheba.health.gov.il
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article, unless otherwise stated.money consuming, other methods aiming to prevent OHSS
while maintaining reasonable IVF outcome were suggested.
In 2000, Itskovitz-Eldor et al. [1] described the first
series of patients, at risk to develop severe OHSS, that
underwent COH using the GnRH- antagonist with
GnRH-agonist (GnRHa) trigger for final follicular matur-
ation. While 50 % conceived, none of the patients devel-
oped any signs or symptoms of OHSS. Controlled
ovarian hyperstimulation (COH) which combines GnRH
antagonist co-treatment and GnRHa trigger has since
become a common tool aiming to eliminate severe early
OHSS and to support the concept of an OHSS-free
clinic [2, 3]. However, due to the reported significantly
reduced clinical pregnancy and increased first trimester
pregnancy loss [4, 5], efforts have been made to improve
reproductive outcome by manipulating the luteal phase.
One of the suggested optional strategies aiming to im-
prove outcome was the addition of low-dose (1500 IU)
HCG bolus.distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
Orvieto Journal of Ovarian Research  (2015) 8:60 Page 2 of 6GnRHa and hCG in patients at risk to develop
severe OHSS (Fig. 1)
One bolus of 1500 IU hCG 35 h after the triggering bolus
of GnRHa, i.e. one hour after oocyte retrieval [6, 7], was
demonstrated to rescue the luteal phase, resulting in a re-
productive outcome comparable with that of HCG trigger-
ing, and with no increased risk of OHSS [8]. However,
when applied to patients at high-risk to develop severe
OHSS, 26 % developed severe early OHSS requiring ascites
drainage and hospitalization [9]. A figure that is compar-
able to the acceptable 20 % prevalence of severe OHSS
in ostensibly high risk patients [10].
One bolus of 1500 IU hCG concomitant with GnRHa
(dual trigger), 34–36 h before oocyte retrieval was sug-
gested as a method which improves oocyte maturation,
while providing more sustained support for the corpus
luteum than can be realized by the GnRHa-induced
LH surge alone [11, 12]. However, while acceptable
rates of fertilization, implantation, clinical pregnancy,
ongoing pregnancy rates, and early pregnancy loss
were achieved in high responders after dual trigger
[11, 12], the incidence of clinically significant OHSS
was not eliminated, but rather reduced to 0.5 % [12].
One bolus of 1500 IU hCG five days after the triggering
bolus of GnRHa [13, 14]. While the freeze-all policy was
applied to all patients yielding more than 20 oocytes,
those triggered with GnRHa, who achieved less than 20
oocytes, were instructed to start an intensive luteal sup-
port with estradiol and progesterone, the day following
OPU, and were re-evaluated 3 days after oocyte retrieval
(on day of embryo transfer) for signs of early moderate
OHSS (ultrasonographic signs of ascites as reflected by
the appearance of fluid surrounding the uterus/ovaries,
and/or Hct levels >40 % for the degree of haemoconcen-








Fig. 1 GnRHa and hCG trigger in patients at risk to develop severe OHSSembryo was transferred, and the patients were instructed
to inject 1500 IU of HCG. By deferring the hCG bolus
by 3 days (5 days following GnRHa trigger), the corpus
luteum was rescued, with an observed extremely high
midluteal progesterone levels [14], reasonable pregnancy
rate, with no patient developing severe OHSS. However,
while these preliminary results are promising, the small
sample size mandates further large prospective random-
ized studies [14].
GnRHa versus hCG trigger- the physiological
perspectives
In the course of the ovulatory cycle, sufficient production
of estradiol by the preovulatory follicle induces the mid
cycle LH surge, which is followed by a loss of gap junctions
between the oocyte and cumulus cells, cumulus expansion,
germinal vesicle breakdown, resumption of meiosis and
luteinization of the granulosa cells. Moreover, the conse-
quent increase in progesterone synthesis facilitates the posi-
tive feedback action of estradiol to induce the concomitant
midcycle FSH peak [15]. This peak FSH has several roles,
including the assurance of an adequate complement of
LH receptors on the granulosa layer and the synthesis
of hyaluronic acid matrix that facilitates the expansion
and dispersion of the cumulus cells, allowing the
oocyte-cumulus cell mass to become free-floating in
the antral fluid [15].
As part of a standard/conventional COH regimen,
final oocyte maturation and resumption of meiosis are
usually triggered by one bolus of hCG (5000–10,000
units), that is administered as close as possible to the
time of ovulation (i.e. 36 h before oocyte recovery [16].
In 1990, Gonen et al. [17] have demonstrated that ovula-
tion may be also triggered by GnRHa, causing the re-
lease of both endogenous LH and FSH, mimicking thePU
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physiologic.
As a consequence of the aforementioned observations,
several studies have emerged, comparing the effect of
hCG versus GnRHa trigger on the different follicular
maturation variables following an IVF treatment cycle.
The number of oocytes retrieved, percentage of mature
oocytes and number of top-quality embryos were either
comparable or in favor of the GnRHa trigger (Table 1)
[18–22] and might be explained by the following
observations:
1. Unlike the GnRHa-induced mid-cycle surge of LH
and FSH, terminating 24 h after its onset, the
HCG-mediated LH activity, with no FSH rise, and
spans several days into the luteal phase [18].
2. While both LH and hCG act on the same LH
receptor, accumulating evidence suggests that LH
has a greater impact on AKT and extracellular
signal regulated protein kinase (ERK1/2)
phosphorylation, responsible for granulosa cells
proliferation, differentiation and survival, while
hCG generates higher intracellular cAMP
accumulation, which stimulates steroidogenesis
(progesterone production) [23].
GnRHa and hCG in patients not at risk to develop
severe OHSS (Fig. 2)
The aforementioned observations demonstrating a
comparable or even better oocyte\embryos maturity and
quality following GnRHa trigger, as compared to hCG
trigger, and the different effects of LH and hCG on the
downstream signaling of the LH receptor, have led to a
new strategy for final follicular maturation, the concomi-
tant administration of both GnRHa and a standard bolus
of hCG (5000–10,000 units) prior to oocyte retrieval,
aiming to improve oocyte and embryo quality and the
consequent IVF cycle outcome.
Standard hCG dose concomitant with GnRHa (dual
trigger), 35–37 h before oocyte retrieval. Lin et al. [24],
in their retrospective cohort study, have compared IVF
outcome in normal responders patients undergoing
COH using the GnRH antagonist with either a standard
dosage of hCG trigger (6,500 IU of recombinant hCG)Table 1 The effect of GnRHa versus hCG trigger on the different fol
Authors #oocytes #MII oocyte
Fauser et al. [18] =
Kolibianakis et al. [19] = =
Humaidan et al. [20] =
Acevedo et al. [21] = =
Erb et al. [22] > >
>In favor of GnRHaor the dual trigger (0.2 mg of triptorelin and 6,500 IU of
recombinant hCG) 35–36 h prior to oocyte retrieval.
The dual trigger group demonstrated statistically sig-
nificantly higher number of oocytes retrieved, matured
oocytes and number of embryos cryopreserved, with
the consequent significant increase in implantation,
clinical pregnancy and live-birth rates, as compared
with the hCG-only trigger group.
In a subsequent prospective randomized controlled
trial of normal responder patients, Decleer et al. [25]
compared IVF outcome following either, 5000 IU of
hCG trigger or a combination of GnRHa plus 5000 IU of
hCG concomitantly, 36 h prior to oocyte retrieval. While
no in between groups differences were observed in the
mean number of oocytes retrieved, mature oocytes or
pregnancy rates, the number of patients who received at
least one embryo of excellent quality and the number of
cryopreserved embryos were significantly higher follow-
ing the dual trigger.
Griffin et al. [26] evaluated the effect of the dual trig-
ger (GnRHa and hCG 5,000 IU or 10,000 IU, 35–37 h)
prior to oocyte retrieval in patients with a previous his-
tory of >25 % immature oocytes retrieved. Despite a sig-
nificantly higher proportion of mature oocytes
retrieved with the dual trigger, the observed IVF out-
come remained poor, probably due to patients’ under-
lying oocyte dysfunction.
GnRHa 40 h and standard hCG added 34 h prior to
OPU (double trigger), respectively. Recently, Beck-
Fruchter et al. [27] have described a case of recurrent
empty follicle syndrome, successfully treated by ovula-
tion trigger with GnRHa 40 h and hCG added 34 h prior
to oocyte retrieval. They assumed that by prolonging
the time between ovulation triggering and OPU [28]
and the GnRHa trigger with the consequent simultan-
eous induction of an FSH surge, the “double trigger”
could overcome any existing impairments in granulosa
cell function, oocyte meiotic maturation or cumulus
expansion, resulting in successful aspiration of mature
oocytes, pregnancy and delivery.
Prompted by the aforementioned observations, we
offered the double trigger to two group of patients
demonstrating abnormal final follicular maturation
despite normal response to COH, those with lowlicular maturation variables following an IVF treatment cycle






Fig. 2 GnRHa and hCG trigger in patients not at risk to develop severe OHSS
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dominant follicles > 14 mm in diameter on day of hCG
administration [29] and those with low proportion of
mature/ metaphase-II (MII) oocytes (<66 %) per num-
ber oocytes retrieved [30].
In the group of patients with low (<50 %) number of
oocytes retrieved per number of dominant follicles, fol-
lowing the double trigger, patients had significantly
higher number of oocytes retrieved, number of 2PN,
number of embryos transferred and significantly higher
proportions of the number of oocytes retrieved to the
number of follicles >10 mm and >14 mm in diameter on
day of hCG administration, with a tendency toward a
higher number of top-quality embryos, as compared to
the hCG-only trigger cycles [29].Table 2 The effect of Standard hCG dose concomitant with GnRHa
maturation variables following an IVF treatment cycle
Authors #oocytes #MII oocytes # embry
Lin et al. [24] > > >
Decleer et al. [25] = = =
>patient
Cryopres
Griffin et al. [26] > >
Haas et al. [29] > >
Zilberberg et al. [30] > >
>In favor of the dual/double triggerMoreover, in those with low proportion of MII oocytes
(<66 %) per number oocytes retrieved, following the
double trigger, patients yielded significantly higher num-
ber of MII oocytes and proportion of MII oocytes per
number of oocytes retrieved, with the consequent sig-
nificantly increased number of top-quality embryos, as
compared to the hCG-only trigger cycles [30].
To conclude, when the effects of the dual and double
triggers are observed across the aforementioned studies
(Table 2), they are always in the same direction- consist-
ently improved.
Standard hCG dose concomitant with GnRHa (dual trig-
ger), 34 h before oocyte retrieval. According to the Bologna
criteria, the minimal criteria needed to define poor ovarian
respone (POR) are the presence of at least two of the(dual-double trigger) versus hCG alone on the different follicular
os cryopreserved #top quality embryos Pregnancy rate
= >
= =
s with embryos >patients with at least
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(≥40 years) or any other risk factor for POR; (ii) A pre-
vious POR (≤3 oocytes with a conventional stimulation
protocol); and (iii) An abnormal ovarian reserve test
[31]. One of the major unnoticed concern in this group of
poor responders is the observed high prevalence of prema-
ture luteinization\ovulation [32, 33], which may be over-
come by early triggering of final follicular maturation-
while approaching a follicular size of 15–16 mm, and by
shortening the duration between the trigger and OPU.
However, since shortening the interval between hCG
priming and oocyte retrieval may decrease the percent-
age of mature oocytes [28], an additional measure to im-
prove the number of oocytes retrieved to the number of
follicles >10 mm, and the proportion of mature oocytes
should be implemented [29, 30]. One of the suggested
measures, that should be further study, is whether dual
trigger (hCG and GnRHa) administered 34 h prior to
OPU will provide the desired improve results.
Conclusions
In the present review we analyzed and discuss the hitherto
published studies relating to the different mode of GnRHa
combined with hCG trigger- for final follicular maturation,
aiming to elucidate how to tailor each mode to its appropri-
ate subgroup of patients.
One bolus of 1500 IU hCG, concomitant, 35 h or 5 days
after the triggering bolus of GnRHa, were all demonstrated
to rescue the luteal phase, resulting in improved reproduct-
ive outcome in patients at risk to develop severe OHSS, as
compared to GnRHa trigger alone, with the questionable
ability to eliminate severe OHSS.
Moreover, following the observations demonstrating a
comparable or even better oocyte\embryos quality follow-
ing GnRHa trigger as compared to hCG trigger, and the dif-
ferent effects of LH and hCG on the downstream signaling
of the LH receptor, GnRHa is now offered concomitant to
the standard hCG trigger dose, to improve oocyte/embryo
yield and quality. GnRHa and hCG may be offered con-
comitantly, 34–37 h prior to oocyte retrieval (dual trigger)
or 40 h and 34 h prior to oocyte retrieval, respectively
(double trigger) in patients with abnormal final follicular
maturation.
Further large prospective studies are needed to examine
the role of dual/double triggers in the different groups of
patients undergoing IVF, prior to its routine implementa-
tion. Specifically, the ability of deferring the 1500 IU of
hCG bolus to the day of embryo transfer to eliminate
OHSS and the role of dual trigger 34 h prior to oocyte re-
trieval in poor responder patients, should be elucidated.
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